Today
+2.15%
5 Days
-1.89%
1 Month
+8.51%
6 Months
+33.84%
Year to Date
+29.02%
1 Year
+37.39%
• Market sentiment shifted capital toward high-yielding defensive equities and consumer staples. • Share buyback execution and insider purchasing disclosures boosted investor confidence. • Annual revenue reached $33.73 billion with net profit at $10.23 billion.
• Philip Morris reported an annual revenue of $40.65B and net profit of $11.32B. • Smoke-free products like IQOS and ZYN drive revenue growth and margin expansion. • Analysts maintain Buy ratings with an average price target of $202.71.
• Third-quarter financial results exceeded Wall Street revenue and earnings expectations. • International operations posted high single-digit organic sales growth and margin expansion. • Full-year core earnings outlook was adjusted due to elevated expenses.
• Philip Morris attracted institutional buying due to its resilient balance sheets and dividends. • Smoke-free products drive momentum, generating over forty percent of total revenues. • Analysts maintain buy ratings with an average price target of $202.09.
• JBS shares rebounded due to technical oversold conditions and heavy call option buying. • Investors favored the strategic consolidation of Pilgrim's Pride to unlock operational synergies. • Analysts reaffirmed positive ratings, highlighting strong international operations and attractive dividend yields.
• Management raised full-year and third-quarter adjusted earnings per share guidance. • ZYN oral nicotine pouch growth drives smoke-free product momentum. • Annual revenue reached $40.65B with net profit totaling $11.32B.
Philip Morris International (PM) Q3 2026 Earnings Call: Smoke-Free Growth and Outlook


| Shareholders | Proportion |
|---|---|
| Capital World Investors | 8.49% |
| Capital International Investors | 6.50% |
| Vanguard Capital Management, LLC | 6.49% |
| BlackRock Institutional Trust Company, N.A. | 5.19% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 57.80% |
| Investment Advisor/Hedge Fund | 18.85% |
| Research Firm | 2.15% |
| Bank and Trust | 1.99% |
Related Instruments